Objective: reduce community % rate of infected HSV-2 individuals.
How: develop a vaccine that can reduce the chance of infection/spreading for both non-infected and infected individuals.
* Reduction in outbreaks is vital, as that is when the virus is most transmittable/active.
* Reduction is shedding is vital, as that is where the majority of transmission occurs unwittingly.
* Admedus' vaccine is interesting, as it can be applied to both infected and non-infected individuals, and obtain a benefit for both. Uninfected people will presumably build a level of immunity (although, not 100%) and infected people will reduce their transmit-ability somewhat.
This approach should statistically reduce the spread/level of HSV-2 within the community?
Not eradication - but improvement.
The other vaccines/scientists getting a lot of attention for their vaccine (RVx Rational Vaccine, etc) are getting their attention via PR firms - not due to the results.
As far as I can see, Admedus has the best reduction in shedding (58%) (although, I note Genoca now also quoting 58% for their vaccine in some places........) and the certain best in outbreaks at 90%.
Something in the technology is working. I suspect it can be improved upon.
Cheers
- Forums
- ASX - By Stock
- Most undervalued stock
Objective: reduce community % rate of infected HSV-2...
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M |
Open | High | Low | Value | Volume |
$18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 73 | $18.31 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.33 | 90 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 73 | 18.310 |
1 | 150 | 18.100 |
1 | 20 | 18.060 |
1 | 100 | 18.050 |
1 | 250 | 18.010 |
Price($) | Vol. | No. |
---|---|---|
18.330 | 90 | 1 |
19.000 | 9589 | 2 |
19.030 | 467 | 1 |
19.290 | 325 | 1 |
19.800 | 264 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online